Healthcare / BiotechnologyStockholm
$1.23
+0.02 (+1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-53.9M · quality 75.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$419M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-29.4%
↓Gross Margin
-57.2%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+27.5%
FCF CAGR
—
FCF margin
-333.1%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.1M · net income $-80.8M · FCF $-66.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.1M | $20.1M | $11.8M | $8.0M | $9.7M |
| Net Income | $-80.8M | $-80.8M | $-75.5M | $-102.9M | $-64.2M |
| EBITDA | $-62.2M | $-62.2M | $-56.9M | $-66.7M | $-43.2M |
| EPS | -0.27 | -0.27 | -1.00 | -1.36 | -1.10 |
| Gross Margin | -57.2% | -57.2% | -29.9% | -172.1% | 34.8% |
| Operating Margin | -415.7% | -415.7% | -655.6% | -1167.5% | -665.1% |
| Net Margin | -402.3% | -402.3% | -640.7% | -1283.2% | -662.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.46 | 6.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-66.9M | $-66.9M | $-53.9M | $-47.9M | $-75.9M |
| Returns | |||||
| ROE | -29.4% | -29.4% | -46.5% | -43.2% | -25.6% |
| Valuation | |||||
| P/B | 1.33 | 1.33 | 0.45 | 2.26 | 5.39 |
| Growth & Yield | |||||
| Revenue Growth | 70.4% | 70.4% | 47.1% | -17.2% | — |
| EPS Growth | 73.0% | 73.0% | 26.7% | -24.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.00 → -0.27
Residual
+17.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.